Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure

Thomas Delate, Erin J. Aiello Bowles, Roy Pardee, Robert D. Wellman, Laurel A. Habel, Marianne Ulcickas Yood, Larissa Nekhlyudov, Katrina A. Goddard, Robert Davis, Catherine A. McCarty, Adedayo A. Onitilo, Heather Spencer Feigelson, Jared Freml, Edward Wagner

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Cancer Research Network (CRN) sites use administrative data to populate their Virtual Data Warehouse (VDW). However, information onVDWchemotherapy data validity is limited. The purpose of this study was to assess the validity of VDW chemotherapy data. Methods: This was a retrospective cohort study of women ≥18 years with incident, invasive breast cancer diagnosed between January 1999 and December 2007. Pharmacy and procedure chemotherapy data were extracted from each site's VDW. Random samples of 50 patients stratified on trastuzumab, anthracyclines, and no chemotherapy exposure was selected from each site for detailed chart abstraction. Weighted sensitivities and specificities of VDW compared with abstracted data were calculated. Cumulative doses calculated from VDW data were compared with doses obtained from the medical chart review. Results: The cohort included 13,497 patients with 6,456 (48%) chart review eligible. Patients in the sample (N = 400) had a mean age of 65 years. Trastuzumab, anthracycline, and other chemotherapy weighted sensitivities were 95%, 97%, and 100%, respectively; specificities were 99%, 99%, and 93%, respectively; positive predictive values were 96%, 99%, and 55%, respectively; and negative predictive values were 99%, 96%, and 100%. Trastuzumab and anthracyclinesVDWmean doseswere 873 and 386mg, respectively,whereas abstracted mean doses were 1,734 and 369 mgs, respectively (R 2 = 0.14, P < 0.01 and R 2 = 0.05, P = 0.03, respectively). Conclusions: Sensitivities and specificities for CRN chemotherapy VDW data were high and dosages were correlated with chart information. Impact: The findings support the use of CRN data in evaluating chemotherapy exposures and related outcomes.

Original languageEnglish (US)
Pages (from-to)673-680
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume21
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Breast Neoplasms
Delivery of Health Care
Drug Therapy
Anthracyclines
Research
Sensitivity and Specificity
Neoplasms
Cohort Studies
Retrospective Studies
Trastuzumab

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. / Delate, Thomas; Aiello Bowles, Erin J.; Pardee, Roy; Wellman, Robert D.; Habel, Laurel A.; Yood, Marianne Ulcickas; Nekhlyudov, Larissa; Goddard, Katrina A.; Davis, Robert; McCarty, Catherine A.; Onitilo, Adedayo A.; Feigelson, Heather Spencer; Freml, Jared; Wagner, Edward.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 21, No. 4, 01.04.2012, p. 673-680.

Research output: Contribution to journalArticle

Delate, T, Aiello Bowles, EJ, Pardee, R, Wellman, RD, Habel, LA, Yood, MU, Nekhlyudov, L, Goddard, KA, Davis, R, McCarty, CA, Onitilo, AA, Feigelson, HS, Freml, J & Wagner, E 2012, 'Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure', Cancer Epidemiology Biomarkers and Prevention, vol. 21, no. 4, pp. 673-680. https://doi.org/10.1158/1055-9965.EPI-11-1075
Delate, Thomas ; Aiello Bowles, Erin J. ; Pardee, Roy ; Wellman, Robert D. ; Habel, Laurel A. ; Yood, Marianne Ulcickas ; Nekhlyudov, Larissa ; Goddard, Katrina A. ; Davis, Robert ; McCarty, Catherine A. ; Onitilo, Adedayo A. ; Feigelson, Heather Spencer ; Freml, Jared ; Wagner, Edward. / Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. In: Cancer Epidemiology Biomarkers and Prevention. 2012 ; Vol. 21, No. 4. pp. 673-680.
@article{858abeba506849a495edde38a293c032,
title = "Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure",
abstract = "Background: Cancer Research Network (CRN) sites use administrative data to populate their Virtual Data Warehouse (VDW). However, information onVDWchemotherapy data validity is limited. The purpose of this study was to assess the validity of VDW chemotherapy data. Methods: This was a retrospective cohort study of women ≥18 years with incident, invasive breast cancer diagnosed between January 1999 and December 2007. Pharmacy and procedure chemotherapy data were extracted from each site's VDW. Random samples of 50 patients stratified on trastuzumab, anthracyclines, and no chemotherapy exposure was selected from each site for detailed chart abstraction. Weighted sensitivities and specificities of VDW compared with abstracted data were calculated. Cumulative doses calculated from VDW data were compared with doses obtained from the medical chart review. Results: The cohort included 13,497 patients with 6,456 (48{\%}) chart review eligible. Patients in the sample (N = 400) had a mean age of 65 years. Trastuzumab, anthracycline, and other chemotherapy weighted sensitivities were 95{\%}, 97{\%}, and 100{\%}, respectively; specificities were 99{\%}, 99{\%}, and 93{\%}, respectively; positive predictive values were 96{\%}, 99{\%}, and 55{\%}, respectively; and negative predictive values were 99{\%}, 96{\%}, and 100{\%}. Trastuzumab and anthracyclinesVDWmean doseswere 873 and 386mg, respectively,whereas abstracted mean doses were 1,734 and 369 mgs, respectively (R 2 = 0.14, P < 0.01 and R 2 = 0.05, P = 0.03, respectively). Conclusions: Sensitivities and specificities for CRN chemotherapy VDW data were high and dosages were correlated with chart information. Impact: The findings support the use of CRN data in evaluating chemotherapy exposures and related outcomes.",
author = "Thomas Delate and {Aiello Bowles}, {Erin J.} and Roy Pardee and Wellman, {Robert D.} and Habel, {Laurel A.} and Yood, {Marianne Ulcickas} and Larissa Nekhlyudov and Goddard, {Katrina A.} and Robert Davis and McCarty, {Catherine A.} and Onitilo, {Adedayo A.} and Feigelson, {Heather Spencer} and Jared Freml and Edward Wagner",
year = "2012",
month = "4",
day = "1",
doi = "10.1158/1055-9965.EPI-11-1075",
language = "English (US)",
volume = "21",
pages = "673--680",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure

AU - Delate, Thomas

AU - Aiello Bowles, Erin J.

AU - Pardee, Roy

AU - Wellman, Robert D.

AU - Habel, Laurel A.

AU - Yood, Marianne Ulcickas

AU - Nekhlyudov, Larissa

AU - Goddard, Katrina A.

AU - Davis, Robert

AU - McCarty, Catherine A.

AU - Onitilo, Adedayo A.

AU - Feigelson, Heather Spencer

AU - Freml, Jared

AU - Wagner, Edward

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: Cancer Research Network (CRN) sites use administrative data to populate their Virtual Data Warehouse (VDW). However, information onVDWchemotherapy data validity is limited. The purpose of this study was to assess the validity of VDW chemotherapy data. Methods: This was a retrospective cohort study of women ≥18 years with incident, invasive breast cancer diagnosed between January 1999 and December 2007. Pharmacy and procedure chemotherapy data were extracted from each site's VDW. Random samples of 50 patients stratified on trastuzumab, anthracyclines, and no chemotherapy exposure was selected from each site for detailed chart abstraction. Weighted sensitivities and specificities of VDW compared with abstracted data were calculated. Cumulative doses calculated from VDW data were compared with doses obtained from the medical chart review. Results: The cohort included 13,497 patients with 6,456 (48%) chart review eligible. Patients in the sample (N = 400) had a mean age of 65 years. Trastuzumab, anthracycline, and other chemotherapy weighted sensitivities were 95%, 97%, and 100%, respectively; specificities were 99%, 99%, and 93%, respectively; positive predictive values were 96%, 99%, and 55%, respectively; and negative predictive values were 99%, 96%, and 100%. Trastuzumab and anthracyclinesVDWmean doseswere 873 and 386mg, respectively,whereas abstracted mean doses were 1,734 and 369 mgs, respectively (R 2 = 0.14, P < 0.01 and R 2 = 0.05, P = 0.03, respectively). Conclusions: Sensitivities and specificities for CRN chemotherapy VDW data were high and dosages were correlated with chart information. Impact: The findings support the use of CRN data in evaluating chemotherapy exposures and related outcomes.

AB - Background: Cancer Research Network (CRN) sites use administrative data to populate their Virtual Data Warehouse (VDW). However, information onVDWchemotherapy data validity is limited. The purpose of this study was to assess the validity of VDW chemotherapy data. Methods: This was a retrospective cohort study of women ≥18 years with incident, invasive breast cancer diagnosed between January 1999 and December 2007. Pharmacy and procedure chemotherapy data were extracted from each site's VDW. Random samples of 50 patients stratified on trastuzumab, anthracyclines, and no chemotherapy exposure was selected from each site for detailed chart abstraction. Weighted sensitivities and specificities of VDW compared with abstracted data were calculated. Cumulative doses calculated from VDW data were compared with doses obtained from the medical chart review. Results: The cohort included 13,497 patients with 6,456 (48%) chart review eligible. Patients in the sample (N = 400) had a mean age of 65 years. Trastuzumab, anthracycline, and other chemotherapy weighted sensitivities were 95%, 97%, and 100%, respectively; specificities were 99%, 99%, and 93%, respectively; positive predictive values were 96%, 99%, and 55%, respectively; and negative predictive values were 99%, 96%, and 100%. Trastuzumab and anthracyclinesVDWmean doseswere 873 and 386mg, respectively,whereas abstracted mean doses were 1,734 and 369 mgs, respectively (R 2 = 0.14, P < 0.01 and R 2 = 0.05, P = 0.03, respectively). Conclusions: Sensitivities and specificities for CRN chemotherapy VDW data were high and dosages were correlated with chart information. Impact: The findings support the use of CRN data in evaluating chemotherapy exposures and related outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84859398893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859398893&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-11-1075

DO - 10.1158/1055-9965.EPI-11-1075

M3 - Article

VL - 21

SP - 673

EP - 680

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -